Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.

Smith AJ, Li Y, Bazin HG, St-Jean JR, Larocque D, Evans JT, Baldridge JR.

Vaccine. 2016 Aug 5;34(36):4304-12. doi: 10.1016/j.vaccine.2016.06.080. Epub 2016 Jul 9.

2.

TLR4 agonists as immunomodulatory agents.

Alderson MR, McGowan P, Baldridge JR, Probst P.

J Endotoxin Res. 2006;12(5):313-9.

PMID:
17059695
3.

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

Cluff CW, Baldridge JR, Stöver AG, Evans JT, Johnson DA, Lacy MJ, Clawson VG, Yorgensen VM, Johnson CL, Livesay MT, Hershberg RM, Persing DH.

Infect Immun. 2005 May;73(5):3044-52.

4.

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.

Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Persing D.

Expert Opin Biol Ther. 2004 Jul;4(7):1129-38. Review.

PMID:
15268679
5.

Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Stöver AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, Jeffery EW, Johnson DA, Lacy MJ, Baldridge JR, Probst P, Ulevitch RJ, Persing DH, Hershberg RM.

J Biol Chem. 2004 Feb 6;279(6):4440-9. Epub 2003 Oct 21.

6.

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR.

Expert Rev Vaccines. 2003 Apr;2(2):219-29. Review.

PMID:
12899573
7.

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, Brookshire VG, Wang R, Ward JR, Yorgensen YM, Persing DH, Johnson DA.

J Endotoxin Res. 2002;8(6):453-8.

PMID:
12697089
8.

Taking toll: lipid A mimetics as adjuvants and immunomodulators.

Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG.

Trends Microbiol. 2002;10(10 Suppl):S32-7. Review.

PMID:
12377566
9.

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration.

Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT.

Vaccine. 2000 May 8;18(22):2416-25.

PMID:
10738099
10.

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.

Baldridge JR, Crane RT.

Methods. 1999 Sep;19(1):103-7. Review.

PMID:
10525445
11.
12.

Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells.

Baldridge JR, McGraw TS, Paoletti A, Buchmeier MJ.

J Virol. 1997 Jan;71(1):755-8.

13.

An H2-T MHC class Ib molecule presents Listeria monocytogenes-derived antigen to immune CD8+ cytotoxic T cells.

Bouwer HG, Lindahl KF, Baldridge JR, Wagner CR, Barry RA, Hinrichs DJ.

J Immunol. 1994 Jun 1;152(11):5352-60.

PMID:
8189053
14.

Teratogenic effects of neonatal arenavirus infection on the developing rat cerebellum are abrogated by passive immunotherapy.

Baldridge JR, Pearce BD, Parekh BS, Buchmeier MJ.

Virology. 1993 Dec;197(2):669-77.

PMID:
8249289
17.

Induction of immunity with avirulent Listeria monocytogenes 19113 depends on bacterial replication.

Baldridge JR, Thomashow MF, Hinrichs DJ.

Infect Immun. 1988 Aug;56(8):2109-13.

Supplemental Content

Loading ...
Support Center